Hepatic SGLT-2 expression is minimal, but SGLT-2i ameliorate NAFLD and NASH through indirect mechanisms, including reduced hepatic gluconeogenesis, improved insulin sensitivity, and modulation of adipokine signaling, such as increased adiponectin. Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.